EXECUTIVE INSIGHTS
DOMAIN EXPERTS
PLAYERS
PARTICIPANTS
-
JAN 2025
-
EDITION 16
-
TABLES 160
-
REGIONS 13
-
SEGMENTS 15
-
PAGES 415
-
US$ 5600
-
MCP-6954
-
JOIN OUR PANEL
EXECUTIVE ENGAGEMENTS BY TIER
-
CXO
-
VICE PRESIDENT
-
DIRECTOR
-
MANAGER
-
MARKETING
HIGHLIGHTS & REPORT INDEX
Global Metabolomics Market to Reach US$7.1 Billion by 2030
The global market for Metabolomics estimated at US$3.3 Billion in the year 2023, is expected to reach US$7.1 Billion by 2030, growing at a CAGR of 11.6% over the analysis period 2023-2030. Cancer Indication, one of the segments analyzed in the report, is expected to record a 13.0% CAGR and reach US$3.6 Billion by the end of the analysis period. Growth in the Cardiovascular Disorder Indication segment is estimated at 10.3% CAGR over the analysis period.
The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 14.0% CAGR
The Metabolomics market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$687.2 Million by the year 2030 trailing a CAGR of 14.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.5% and 11.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.6% CAGR.
SCOPE OF STUDY
The report analyzes the Metabolomics market by the following Segments, and Geographic Regions/Countries:
Segments:
Indication (Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication, Other Indications); Application (Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application, Other Applications); End-Use (Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use, Other End-Uses).
Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World..
SELECT PLAYERS
AB Sciex LLC; Agilent Technologies, Inc.; Biocrates Life Sciences Ag; Bruker Corporation; Chenomx, Inc.; GL Sciences Inc.; Human Metabolome Technologies, Inc.; LECO Corporation; Metabolon, Inc.; PerkinElmer, Inc.; Shimadzu Scientific Instruments; Thermo Fisher Scientific, Inc.; Waters Corporation
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Metabolomics: Transforming Healthcare with Insight into Metabolic Pathways and Biomarkers |
Global Economic Update |
EXHIBIT: World Economic Growth Projections (Real Gross Domestic Product (GDP), Annual % Change) for the Years 2022 Through 2025 |
EXHIBIT: Global Headline Inflation Rates (In %) for the Years 2019 through 2025 |
EXHIBIT: Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2019 through 2025 |
Metabolomics – Global Key Competitors Percentage Market Share in 2024 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for 63 Players Worldwide in 2024 (E) |
Introduction to Metabolomics |
Analytical Techniques in Metabolomics |
The Metabolomics Workflow: Key Stages |
Applications of Metabolomics |
Recent Market Activity |
Influencer/Product/Technology Insights |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
Development of Novel Biomarkers for Disease Detection Drives Widespread Adoption of Metabolomics in Clinical Diagnostics |
Metabolomics in Drug Research and Development: A Pathway to Precision Medicine |
Growing Focus on Personalized Healthcare and Patient-Centric Solutions Expands Addressable Market for Targeted Metabolomics Applications |
EXHIBIT: Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025 |
Growing Multidisciplinary Role of Metabolomics in Toxicology Testing |
Rising Demand for Nutrigenomics Throws the Spotlight on Nutritional Metabolomics Applications for Customized Diet Planning |
Growing Investment in Cancer Research Propels Growth in Oncology-Focused Metabolomics Studies and Applications |
EXHIBIT: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2022 and 2050 |
EXHIBIT: Global Cancer Incidence by Region: 2022 |
Integration of AI, Machine Learning, and Big Data Analytics Expands the Potential of Metabolomics Data for Predictive Modeling and Insights |
Advancements in Mass Spectrometry and Analytical Tools Strengthen the Business Case for Large-Scale Metabolomics Research |
Global Shift Toward Precision Medicine Accelerates Adoption Of Metabolomics |
Role of Metabolomics in Inborn Errors of Metabolism (IEMs): Current Advancements and Future Directions |
Harnessing Metabolomics for Crop Improvement and Sustainable Agriculture |
4. GLOBAL MARKET PERSPECTIVE |
World Metabolomics Market Analysis of Annual Sales in US$ Thousand for Years 2018 through 2030 |
World Recent Past, Current & Future Analysis for Metabolomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Metabolomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Metabolomics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2018, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Cancer Indication by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Cardiovascular Disorder Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Cardiovascular Disorder Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Cardiovascular Disorder Indication by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Neurological Disorder Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Neurological Disorder Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Neurological Disorder Indication by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Inborn Errors of Metabolism Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Inborn Errors of Metabolism Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Inborn Errors of Metabolism Indication by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Biomarker Discovery Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Biomarker Discovery Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Biomarker Discovery Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Drug Discovery Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Drug Discovery Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Drug Discovery Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Toxicology Testing Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Toxicology Testing Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Toxicology Testing Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Nutrigenomics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Nutrigenomics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Nutrigenomics Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Personalized Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Personalized Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Personalized Medicine Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Contract Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Contract Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Contract Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030 |
III. MARKET ANALYSIS |
UNITED STATES |
Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E) |
USA Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
USA Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
USA 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030 |
USA Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
USA Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
USA 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030 |
USA Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
USA Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
USA 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030 |
CANADA |
Canada Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Canada Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Canada 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030 |
Canada Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Canada Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Canada 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030 |
Canada Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Canada Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Canada 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030 |
JAPAN |
Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E) |
Japan Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Japan Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Japan 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030 |
Japan Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Japan Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Japan 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030 |
Japan Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Japan Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Japan 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030 |
CHINA |
Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E) |
China Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
China Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
China 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030 |
China Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
China Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
China 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030 |
China Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
China Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
China 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030 |
EUROPE |
Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E) |
Europe Recent Past, Current & Future Analysis for Metabolomics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR |
Europe Historic Review for Metabolomics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Europe 12-Year Perspective for Metabolomics by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2018, 2024 & 2030 |
Europe Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Europe Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Europe 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030 |
Europe Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Europe Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Europe 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030 |
Europe Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Europe Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Europe 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030 |
FRANCE |
Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E) |
France Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
France Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
France 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030 |
France Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
France Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
France 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030 |
France Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
France Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
France 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030 |
GERMANY |
Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E) |
Germany Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Germany Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Germany 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030 |
Germany Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Germany Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Germany 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030 |
Germany Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Germany Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Germany 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030 |
ITALY |
Italy Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Italy Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Italy 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030 |
Italy Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Italy Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Italy 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030 |
Italy Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Italy Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Italy 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030 |
UNITED KINGDOM |
Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E) |
UK Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
UK Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
UK 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030 |
UK Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
UK Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
UK 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030 |
UK Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
UK Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
UK 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of Europe Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Rest of Europe 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of Europe Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Rest of Europe 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of Europe Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Rest of Europe 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030 |
ASIA-PACIFIC |
Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Asia-Pacific Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Asia-Pacific 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Asia-Pacific Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Asia-Pacific 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Asia-Pacific Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Asia-Pacific 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030 |
REST OF WORLD |
Rest of World Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of World Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Rest of World 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030 |
Rest of World Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of World Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Rest of World 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030 |
Rest of World Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of World Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR |
Rest of World 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030 |
IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com